Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lebwohl

Showing results (281-290 of 418) with videos related to

Pageof 42
Sort By:
Journal of the American Academy of Dermatology|August 20, 2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registryAlexis Ogdie, Ryan W Harrison, Robert R McLean, et al.
Dermatology and Therapy|February 23, 2022
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-AnalysisAndrew Blauvelt, Melinda Gooderham, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Dermatology and Therapy|October 27, 2021
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
Journal of the American Academy of Dermatology|June 5, 2021
Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trialIltefat Hamzavi, David Rosmarin, John E Harris, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 14, 2023
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient SurveyJonathan I Silverberg, Jennifer A Mohawk, Joshua Cirulli, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B Gottlieb, Mark Lebwohl, Mark C Totoritis, et al.
Dermatology and Therapy|January 6, 2022
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
Pageof 42

Showing results (281-290 of 418) with videos related to

Sort By:
Pageof 42
Journal of the American Academy of Dermatology|August 20, 2022
Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registryAlexis Ogdie, Ryan W Harrison, Robert R McLean, et al.
Dermatology and Therapy|February 23, 2022
Cumulative Clinical Benefits of Biologics in the Treatment of Patients with Moderate-to-Severe Psoriasis over 1 Year: a Network Meta-AnalysisAndrew Blauvelt, Melinda Gooderham, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|May 14, 2023
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trialBruce Strober, Carle Paul, Andrew Blauvelt, et al.
The Lancet. Rheumatology|January 22, 2024
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind studyKim Papp, Richard B Warren, Lawrence Green, et al.
Dermatology and Therapy|September 16, 2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with PsoriasisMatthias Augustin, Alice B Gottlieb, Mark Lebwohl, et al.
Dermatology and Therapy|October 27, 2021
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
Journal of the American Academy of Dermatology|June 5, 2021
Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trialIltefat Hamzavi, David Rosmarin, John E Harris, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|March 14, 2023
Burden of Disease and Unmet Needs in Atopic Dermatitis: Results From a Patient SurveyJonathan I Silverberg, Jennifer A Mohawk, Joshua Cirulli, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B Gottlieb, Mark Lebwohl, Mark C Totoritis, et al.
Dermatology and Therapy|January 6, 2022
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) SurveyMark Lebwohl, Richard G Langley, Carle Paul, et al.
Pageof 42